Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Combination of viral and bacterial antigens
Reexamination Certificate
2007-01-30
2007-01-30
Graser, Jennifer E. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Combination of viral and bacterial antigens
C424S202100, C424S203100, C424S184100, C424S234100, C424S264100, C424S220100, C424S204100, C424S211100, C424S221100, C424S206100, C424S209100, C424S093100, C424S093400
Reexamination Certificate
active
11318983
ABSTRACT:
The invention provides an improvedMycoplasma hyopneumoniaebacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivatedMycoplasma hyopneumoniaebacterin and an adjuvant mixture, which, in combination, provide immunity fromMycoplasma hyopneumoniaeinfection after a single administration, and elicit an immune response specific toMycoplasma hyopneumoniaebacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA. In another embodiment, the invention provides an improvedMycoplasma hyopneumoniaebacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivatedMycoplasma hyopneumoniaebacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity fromMycoplasma hyopneumoniaeinfection after a single administration, and elicit an immune response specific toMycoplasma hyopneumoniaebacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.
REFERENCES:
patent: 6632439 (2003-10-01), Liem et al.
patent: 0 315 153 (1989-05-01), None
patent: WO 91/18627 (1991-12-01), None
patent: WO 92/03157 (1992-03-01), None
patent: WO 95/30437 (1995-11-01), None
Allison, A. C., “Squalene and Squalane Emulsions as Adjuvants,” Methods 19:87-93, 1999.
Goodwin et al., “Enzootic Pneumonia of Pigs: Immunization Attempts InoculatingMycoplasma suipneumoniaeAntigen by Various Routes and with Different Adjuvants,” British Vet. J. 129(5):456-464, Sep.-Oct. 1973.
Byars et al., “Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity,” Vaccine, 5:223-228, Sep. 1987.
Chu Hsien-Jue
Li Wumin
Xu Zhichang
Graser Jennifer E.
Mandel Adley F.
Rosenblum Anne M.
Wyeth
LandOfFree
Mycoplasma hyopneumoniae bacterin vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mycoplasma hyopneumoniae bacterin vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mycoplasma hyopneumoniae bacterin vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3750371